Analysts are estimating that Novavax will report an earnings per share (EPS) of $-0.87. Anticipation surrounds Novavax's announcement, with investors hoping to hear about both surpassing estimates and ...
Deep-pocketed investors have adopted a bullish approach towards Novavax NVAX, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...